This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
BriefAI

Autonomous Drug Design Platform PharmAI Completes First Fully AI-Driven New Drug Application

Insilico Medicine's PharmAI platform independently designed a new molecule for idiopathic pulmonary fibrosis, completing the entire process from target discovery to preclinical data generation without human chemists, and has submitted an IND application to the FDA.

Insilico Medicine announced on January 16, 2029, that its PharmAI platform has submitted the first entirely AI-designed and validated new drug clinical trial application to the FDA. The drug targets idiopathic pulmonary fibrosis (IPF), a fatal lung disease currently lacking effective treatments.

Traditional new drugs take an average of 4.5 years and $2.6 billion from target discovery to IND application. PharmAI compressed this timeline to 11 months, reducing total costs to approximately $34 million. The platform independently completed the entire process of target validation, lead compound design, ADMET prediction, and preclinical safety assessment.

Insilico Medicine's Chief Medical Officer Alex Zhavoronkov stated: "The molecule designed by PharmAI exhibited 3 times higher target affinity than existing candidates in in vitro experiments, with toxicity prediction indicators significantly superior to controls."

The FDA indicated it will conduct a standard review process, with an IND approval decision expected in Q2 2029. If approved, the drug will enter Phase I clinical trials. This event could redefine the pharmaceutical industry's R&D model.